The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40-49 and 50-59.
Anna Nathalie WilkinsonJean-Michel BilletteLarry F EllisonMichael A KillipNayaar IslamJean Morag SeelyPublished in: Current oncology (Toronto, Ont.) (2022)
The relationship between Canadian mammography screening practices for women 40-49 and breast cancer (BC) stage at diagnosis in women 40-49 and 50-59 years was assessed using data from the Canadian Cancer Registry, provincial/territorial screening practices, and screening information from the Canadian Community Health Survey. For the 2010 to 2017 period, women aged 40-49 were diagnosed with lesser relative proportions of stage I BC (35.7 vs. 45.3%; p < 0.001), but greater proportions of stage II (42.6 vs. 36.7%, p < 0.001) and III (17.3 vs. 13.1%, p < 0.001) compared to women 50-59. Stage IV was lower among women 40-49 than 50-59 (4.4% vs. 4.8%, p = 0.005). Jurisdictions with organised screening programs for women 40-49 with annual recall (screeners) were compared with those without (comparators). Women aged 40-49 in comparator jurisdictions had higher proportions of stages II (43.7% vs. 40.7%, p < 0.001), III (18.3% vs. 15.6%, p < 0.001) and IV (4.6% vs. 3.9%, p = 0.001) compared to their peers in screener jurisdictions. Based on screening practices for women aged 40-49, women aged 50-59 had higher proportions of stages II (37.2% vs. 36.0%, p = 0.003) and III (13.6% vs. 12.3%, p < 0.001) in the comparator versus screener groups. The results of this study can be used to reassess the optimum lower age for BC screening in Canada.